ClinicalTrials.gg
Not yet recruitingNCT07451665VIVA-TAKUpdated Mar 5, 2026

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

A Phase 4 interventional study of Vanakizumab and Ivarmacitinib in Takayasu Arteritis (TAK), sponsored by Chinese SLE Treatment And Research Group. Not yet recruiting at 20 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Chinese SLE Treatment And Research Group · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Takayasu Arteritis with a site in China — 15 open to participants now, 16 under way, 2 of them phase 3. Takayasu Arteritis · China.

Planned enrollment
Largest of 15
180 · median 76
Started
2026
the only one that year
Phase 4
7 of 26
6 open now
Primary completion
2029-03
later than 12 of 15 live
Registered
25th of 26
by date
Lead sponsor
5 of 26
Chinese SLE Treatment And Research Group

Among the 26 studies in Takayasu Arteritis with a site in China, this one has the largest planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 4, reaches primary completion later than 12 of the 15 other live ones, and was the 25th registered.

Takayasu Arteritis

79 studies on the registry are indexed under Takayasu Arteritis; 33 are open to participants now.

Browse Takayasu Arteritis studies →

Open to participants now

15 of the 26 studies in Takayasu Arteritis with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Takayasu Arteritis studies recruiting now, 13 (52%) set no upper age limit and 10 (40%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Takayasu Arteritis with a site in China, or all of them as a file.
02

Study summary

This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.

Read the detailed description

In this study, 180 Takayasu's arteritis patients with active disease will be enrolled. Patients are randomized in to the vunakizumab treatment group, ivarmacitinib treatment group and glucocorticoid treatment group. Patients will follow the same reduction steps for glucocorticoids. The primary endpoint is the percentage of patients who are in complete response at week 52.

The efficacy will be evaluated at week 4, 12, 26, 38 and 52. Safety is also monitored during the study.

03

Conditions studied

  • Takayasu Arteritis (TAK)

Browse trials for

Keywords

  • Vunakizumab
  • Ivarmacitinib
  • randomized controlled trial
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a. Adult patients (aged between 18-70 years) fulfilling the 2022 ACR/EULAR classification criteria for TAK with new-onset or relapsing disease.
  • b. Presence of active disease despite treatment with gluccorticoids combined with a conventional synthetic or biologic agent other than JAK inhibitors and IL-17 inhibitors, including new-onset patients and patients.

Patient is considered to have active disease by the investigator is the patients meets at least two of the following three criteria: i) one or more clinical manifestations determined by the investigator to be due to active TAK; ii) one or more findings on imaging of progressive disease; or iii) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Clinical criteria included constitutional symptoms (fever, fatigue, and weight loss), musculoskeletal symptoms, vascular pain, neurological or visual symptoms, abdominal pain or angina, new or worsening limb claudication, loss of pulses, and worsening hypertension. Imaging criteria includes new vascular stenosis or aneurysms detected by ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography.

Exclusion criteria

Exclusion Criteria:

  • Participants are excluded from the study if any of the following criteria apply:

    1. Medical Conditions

      1. Severe disease from TAK for which urgent treatment with interventional vascular procedures or bypass surgery is considered necessary
      2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia, that is anticipated to need treatment during the study
      3. Active or C virus infection
      4. Active tuberculosis (Patients with latent tuberculosis infection could be enrolled with preventive therapy for tuberculosis flare)
      5. in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)
      6. Poorly controlled diabetes
      7. Patients with history of venous thrombosis
      8. Upper GI bleeding within 3 months prior to enrollment
      9. Uncontrolled heart failure
      10. hypertension
    2. Abnormal Laboratory Test Findings k. Serum liver enzyme elevation 3 times higher than the l. Severe renal function impairment with estimated ≤ 30 ml/minute/1.73 m2, calculated using the Modification of Diet in Renal Disease equation (doi:10.1056/NEJMoa2102953)
    3. Other Exclusion Criteria m. Females who are pregnant or intend to be pregnant during the time frame of the study n. History of treatment with JAKi or IL-17i. o. Any other medical, psychiatric, and/or social reason as determined by the investigator to be a for study participation
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Vunakizumab group (Group Vuna I)

    Vanakizumab 240mg each 4 weeks subcutaneously (with an additional infection at day 15) for 52 weeks combined with glucocorticoid taken daily according to preset tapering protocol during same period

    Drug: Vanakizumab · Drug: Prednisone

  • Experimental
    Ivarmacitinib group (Group Iva I)

    Ivarmacitinib 8mg daily taken orally for 52 weeks combined with glucocorticoid taken daily according to preset tapering protocol during same period

    Drug: Ivarmacitinib · Drug: Prednisone

  • Active comparator
    Prednisone group (Group Pred)

    Prednisone taken daily according to preset tapering protocol for 52 weeks

    Drug: Prednisone

Interventions

  • DrugVanakizumab

    Vanakizumab 240mg each 4 weeks taken subcutaneously with an additional injection at day 15

  • Ivarmacitinib 8mg daily taken orally

  • Prednisone taken daily according to preset tapering protocol

06

What researchers measure

Primary outcomes

  1. Complete response rate at week 52

    Percentage of patients with complete response at week 52

    Time frame: week 52

Secondary outcomes

  1. Complete response at week 26

    Percentage of patients with complete response at week 26

    Time frame: week 26

  2. Combined response rate of vunakizumab at week 26 and week 52

    Percentage of patients with response treated with vunakizumab at week 26 and week 52

    Time frame: week 26 and week 52

  3. Combined response rate of ivarmacitinib at week 26 and week 52

    Percentage of patients with response treated with ivarmacitinib at week 26 and week 52

    Time frame: week 26 and week 52

  4. Time to relapse

    Time to relapse in each treatment group

    Time frame: week 52

  5. Time to event

    Time to event (including relapse, discontinuation due to AE/SAE, treatment failure)

    Time frame: week 52

  6. Patient-Reported Outcomes

    The comparison of PtGA and PhGA in each individual during the treatment in each group

    Time frame: week 52

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Mar 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2026
First posted
Mar 5, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
Mar 31, 2029
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07451665
Lead sponsor
Chinese SLE Treatment And Research Group
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Mar 5, 2026

Study contacts

Xinping TIAN, M.D.
Contact
tianxp6@126.com
+86-13691165939
Jing LI, M.D.
Contact
lijing6515@pumch.cn
+86-13020061363
Xinping TIAN, M.D.
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion